Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure
Abstract
Background Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalizations for heart failure in patients with or without diabetes. More evidence is needed regarding their effects across the broad spectrum of heart failure, including those with a markedly reduced ejection...
Paper Details
Title
Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure
Published Date
May 1, 2021
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History